<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02146651</url>
  </required_header>
  <id_info>
    <org_study_id>BC3-CT008</org_study_id>
    <nct_id>NCT02146651</nct_id>
  </id_info>
  <brief_title>A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes</brief_title>
  <official_title>A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of BioChaperone to insulin lispro may accelerate the onset and shorten the
      duration of action of insulin lispro due to facilitation of the absorption of the insulin
      after subcutaneous injection.

      The aim of the trial is to investigate the dose-response and the dose-exposure relationships
      of BioChaperone insulin lispro under 3 doses, to compare the pharmacokinetics and
      glucodynamic action of BioChaperone insulin lispro at 0.2U/Kg with Humalog® at 0.2 U/Kg and
      to assess safety and tolerability of BioChaperone insulin lispro and Humalog®.

      This is a double-blinded, randomised, four-period crossover phase 2 trial using automated
      12-hour euglycemic clamps in subject with type 1 diabetes mellitus.

      Each subject will be randomly allocated to a sequence of 4 treatments, i.e. with one of three
      single doses of BioChaperone insulin lispro (0.1, 0.2 and 0.4 U/Kg) or one single dose of
      Humalog® (0.2 U/Kg) on 4 separate dosing visits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucodynamic endpoint: Area Under the Curve GIR(0-last)</measure>
    <time_frame>12 hours</time_frame>
    <description>Area under the Glucose Infusion Rate time curve from 0 hours until the end of the clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucodynamic endpoint: GIRMax</measure>
    <time_frame>12 hours</time_frame>
    <description>Maximum Glucose Infusion Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic endpoint: AUC Lisp(0-last)</measure>
    <time_frame>12 hours</time_frame>
    <description>Area under the insulin lispro serum concentration - time curve over the clamp procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic endpoint: Cmax(Lisp)</measure>
    <time_frame>12 hours</time_frame>
    <description>Maximum observed serum insulin lispro concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Tmax(lisp)</measure>
    <time_frame>12 hours</time_frame>
    <description>Time to maximum observed serum insulin lispro concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucodynamic: TGIRmax</measure>
    <time_frame>12 hours</time_frame>
    <description>Time to maximum Glucose Infusion Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tonset of action</measure>
    <time_frame>12 hours</time_frame>
    <description>Time from t=0 until blood glucose concentration has decreased by 5mg.dL (0.3mmol.L) from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: adverse events, local tolerability, vital signs variations, ECG, laboratory safety parameters.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Diabetes Mellitus Type 1</condition>
  <arm_group>
    <arm_group_label>BioChaperone insulin lispro 0.2U/Kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BioChaperone insulin lispro 0.2U/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BioChaperone insulin lispro 0.1U/Kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BioChaperone insulin lispro 0.1U/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BioChaperone insulin lispro 0.4U/Kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BioChaperone insulin lispro 0.4U/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog® 0.2U/Kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Humalog® 0.2U/Kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone insulin lispro 0.2U/Kg</intervention_name>
    <description>Single dose of 0.2U/Kg body weight injected subcutaneously</description>
    <arm_group_label>BioChaperone insulin lispro 0.2U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.1U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.4U/Kg</arm_group_label>
    <arm_group_label>Humalog® 0.2U/Kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone insulin lispro 0.1U/Kg</intervention_name>
    <description>Single dose of 0.1U/Kg body weight injected subcutaneously</description>
    <arm_group_label>BioChaperone insulin lispro 0.2U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.1U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.4U/Kg</arm_group_label>
    <arm_group_label>Humalog® 0.2U/Kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone insulin lispro 0.4U/Kg</intervention_name>
    <description>Single dose of 0.4U/Kg body weight injected subcutaneously</description>
    <arm_group_label>BioChaperone insulin lispro 0.2U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.1U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.4U/Kg</arm_group_label>
    <arm_group_label>Humalog® 0.2U/Kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog®</intervention_name>
    <description>Single dose of 0.2U/Kg body weight injected subcutaneously</description>
    <arm_group_label>BioChaperone insulin lispro 0.2U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.1U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.4U/Kg</arm_group_label>
    <arm_group_label>Humalog® 0.2U/Kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus for at least 12 months

          -  Treated with multiple daily insulin injections of insulin pump for at least 12 months

          -  Body Mass Index (BMI): 18.5-28.0 Kg.m²

        Exclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Receipt of any investigational product within 3 months prior first dosing

          -  Clinically significant abnormalities as judged by the investigator

          -  Any systemic treatment with drugs known to interfere with glucose metabolism

          -  History of alcoholism or drug/chemical abuse as per investigator's judgement

          -  Use of tobacco or nicotine-contained product within 1 year prior to screening

          -  Blood or plasma donation in the past month or more than 500ml within 3 months prior to
             screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grit Andersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselfforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2014</study_first_posted>
  <last_update_submitted>December 9, 2014</last_update_submitted>
  <last_update_submitted_qc>December 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

